VIROPRO Inc., (OTCBB: VPRO)

Dear Reader:

If you’re like many investors, you are looking very favorably at healthcare and biotech companies right now.  Over the past few years some fantastic publicly-traded companies have arisen from these sectors.

Notable among performers in this arena is that many were considered “overnight successes” in the market; stocks with small prices and smaller followings that suddenly were thrust into the spotlight on the heels of their announced successes. The companies, we’re certain, chuckled to themselves about being “overnight successes” after what must have been years of blood, sweat and research & development.

Enter into this context today’s feature, Viropro Inc. (OTCBB: VPRO) and its decisive focus on acquiring companies within the health and biotech umbrella to create a potent assemblage that could dramatically enhance shareholder value. With a deep footprint in the Canadian market where healthcare is government subsidized and efficiency is mandated, Viropro is well positioned to execute its business plan.  The Company has already established itself in China and Brazil and has cultivated the business and regulatory contacts required to operate in these markets and is on schedule with its expansion in these massive territories. Meanwhile, the company continues to search the globe for other beneficial opportunities.

With this week's announcement that a major advancement in biotech and chemistry had been achieved in the science of food and drug addiction, we couldn't think of a better time to introduce Viropro. 

The life sciences always seem to be centered in quality of life issues and when exciting discoveries and successful applications make it to market, those core competencies in a business always result in a stronger bottomline and increased revenues.  Viropro has positioned itself through acquisition to grow into three central markets including: healthcare software solutions, the transfer and licensing of biotech products and the original development of biotech compounds.

With seasoned management coming aboard in the last year and a strategic focus on these three areas, we like the possibilities at hand of this up and coming company.  Today’s profile undoubtedly requires a deeper, more ponderous review than many of our subject companies.  The glitter is not on the top of the box but well worth the effort to find it!
 

About Viropro Inc.

Viropro is an emerging provider of  management, product and technology solutions for the international Life Sciences markets. One mission of the Company is to seek revenue-producing acquisition targets with the goal of establishing a new growth portfolio and a potential for continued shareholder value. On December 18, 2003, this culminated in a Letter of Intent to acquire CNC Holdings Inc.  Headquartered in Montreal, Canada, CNC Holdings Inc. develops and markets proven, innovative management solutions for the healthcare sector. 

The acquisition of CNC will immediately propel Viropro into two fast-growing segments of the life sciences market – healthcare and biotech. Other acquisitions and alliances are also contemplated in coming months. This acquisition will be concluded upon the completion of due diligence and the final confirmation of the S-4 Registration Statement that was filed with the SEC in February 2004.

The other mission at Viropro is the discovery and development of chemical and biological products and processes that will benefit medical science and increase the quality of life.

a

Products and Technology

Viropro has numerous agreements in various stages of completion with several enterprises in Brazil involving both the purchase of licensed products for sale into Brazil, and possible technology transfer, and the licensing of products from Brazil for sales into North America. These products include: 

• Interferon (FDA Approved)
• Rapid Diagnostic Tests (HIV 1&2, Hepatitis B&C, Syphilis, Gonorrhea, Chlamydia, HCG)
• Growth Hormones  (EGF, HGH, FSH)

Management at Viropro intends to also capitalize on a growing availability of ready-to-screen compounds derived from Brazilian biodiversity within the legal framework of the 1992 Convention on Biological Diversity.  These unique compounds and products derive from molecules originating from the Brazilian Rain Forest and Amazon.
 

Viropro's Pyramid software, has emerged as essentially the only product in Canada to provide case-costing as an off-the-shelf, open-architecture, low risk and minimally intrusive software solution.

Launch customers have already been established in the Canadian healthcare market for Pyramid, a comprehensive decision-support software solution adapted and sold under license from a U.S. supplier.  Pyramid allows detailed analysis of all administrative and clinical costs in healthcare environments through “case-costing” methodology, providing healthcare administrators with an effective tool and enabling them to make better decisions.

Within the Healthcare market, achieving costing visibility has been an ongoing challenge especially as government bodies look to streamline and make better use of hospital budgets.  To solve this problem, numerous government-sponsored reports in Canada have recommended the use of “activity-based” or “case-costing based” financial tracking and analysis methods. 

Target Markets for Pyramid include public and private healthcare establishments in Québec, across Canada and select countries internationally, such as Brazil and China. 

a

Viropro In The News

Press Release Source: Central Network Communications Inc. 
Thursday January 15, 11:00 am ET 

MONTREAL--(BUSINESS WIRE)--Jan. 15, 2004--Central Network Communications Inc. (CNC) today provided further details and clarifications on the agreement announced December 18, 2003 for the sale of CNC's operations to Viropro Inc. (OTCBB:VPRO - News). 

Viropro Financial Highlights

To Contact Viropro

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.
Can you afford not to take advantage of this opportunity?

Please email us with your contact information at info@stockupticks.com
Click here for a rate sheet.

---

Stockupticks Safe Harbor Statement: Statements contained in this document, including those pertaining to estimates and related plans, potential mergers and acquisitions, estimates, growth, establishing new markets, expansion into new markets and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made.  StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  MP provides no assurance as to the subject company's plans or ability to effect any planned and/or proposed actions. MP has no first-hand knowledge of management and therefore cannot comment on its capabilities, intent, resources, nor experience and makes no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources believed by MP to be reliable, but MP provides no assurance, and none is given, as to the accuracy and completeness of this information. 

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness.  Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP has been compensated $17,500 by VPRO for preparation and distribution of this report and other advertising services.  This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 1920 Main Street, Suite 980, Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.